Decreased serum paraoxonase 1 (PON1) activity: An additional risk factor for atherosclerotic heart disease in patients with PCOS?

Human Reproduction

Volumn 21, Issue 1, 2006, Pages 104-108

  Dursun, Polat ^a   Demirtaş, Ezgi ^a   Bayrak, Ahmet ^a   Yarali, Hakan ^a,b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Atherosclerotic heart disease; Cardiovascular disease; Insulin resistance; Paraoxonase; Polycystic ovary syndrome

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; MALONALDEHYDE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MENSTRUAL CYCLE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; OXIDATION; PATHOPHYSIOLOGY; PROTEIN MODIFICATION; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS;

EID: 29144485802     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dei284     Document Type: Article

References (42)

1. Abbott CA, Mackness MI, Kumar S, Boulton AJ and Durrington PN (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15,1812-1818.
2. ACOG Practice Bulletin (2003) Polycystic ovary syndrome. Number 41. Int J Gynecol Obstet 80,335-348.
3. Adams J, Polson DW and Franks S (1986) Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 293,355-359.
4. Ak G, Ozgonul M, Sozmen EY, Aslan SL and Sozmen B (2002) Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol 15,144-149.
5. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J and Durrington PN (1999) Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19,330-335.
6. bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L and Lim SK (2003) Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med 34,824-829.
7. Birdsall MA, Farquhar CM and White HD (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126,32-35.
8. Dahlgren E, Janson PO, Johansson S, Lapidus L and Oden A (1992) Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71,599-604.
9. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J and San Millan JL (2003) Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 11,987-996.
10. Fenkçi V, Fenkçi S, Yilmazer M and Serteser M (2003) Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 80,123-126.
11. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F and Bicchiega V (2005) Paraoxonase activity in high-density lipoproteins: A comparison between healthy and obese females. J Clin Endocrinol Metab 90,1728-1733.
12. Fortunato G, Rubba P, Panico S, Trono D, Tinto N, Mazzaccara C, De Michele M, Iannuzzi A, Vitale DF, Salvatore F et al. (2003) A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 167,141-148.
13. Gan KN, Smolen A, Eckerson HW and La Du BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19,100-106.
14. Graf M, Richards CJ, Brown V, Meissner L and Dunaif A (1990) The independent effects of hyperandrogenaemia, hyperinsulinaemia and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol 33,119-131.
15. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH and Wolfson SK Jr (1996) Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am J Obstet Gynecol 174,1224-1229, discussion 1229-1232.
16. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nichols DP and Young IS (1998) Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 44,179-181.
17. Holte J, Bergh T, Berne C and Lithell H (1994) Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: Relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol 41,463-471.
18. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y and Hashimoto K (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15,1812-1818.
19. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Hiroyuki I, Kumon Y and Hushimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with noninsulin-dependent diabetes mellitus. Metabolism 47,598-602.
20. James RW, Leviev I, Ruiz J, Passa P, Froguel P and Garin MC (2000) Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49,1390-1393.
21. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD and Furlong CE (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20,2441-2447.
22. Jialal I and Devaraj S (1996) Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: A clinical biochemistry perspective. Clin Chem 42,498-506.
23. Jung HH, Choi DH and Lee SH (2004) Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol 24,537-542.
24. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR and Azziz R (1998) Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 83,3078-3082.
25. Leviev I, Kalix B, Brulhart Meynet MC and James RW (2001) The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia 44,1177-1183.
26. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M and Durrington PN (1991) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86,193-199.
27. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJ and Durrington PN (1998a) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in noninsulin dependent diabetes mellitus. Atherosclerosis 139,341-349.
28. Mackness B, Durrington NP and Mackness MI (1998b) Human serum paraoxonase. Gen Pharmacol 31,329-336.
29. Mackness MI, Mackness B and Durrington PN (2002) Paraoxonase and coronary heart disease. Atheroscler Suppl 3,49-55.
30. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28,412-419.
31. Peral B, San Millan JL, Castello R, Moghetti P and Escobar-Morreale HF (2002) The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 87,3977-3983.
32. Polidori MC, Savino K, Alunni G, Freddio M, Senin U, Sies H, Stahl W and Mecocci P (2002) Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: Relationship to disease severity. Free Radic Biol Med 32,148-152.
33. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19,41-47.
34. Rudich A, Kozlovsky N, Potashnik R and Bashan N (1997) Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 272,E935-E940.
35. Sabuncu T, Vural H, Harma M and Harma M (2001) Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34,407-413.
36. Sakai T, Matsuura B and Onji M (1998) Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 37,581-584.
37. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B and Escobar-Morreale HF (2004) Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89,2640-2646.
38. Slatter DA, Bolton CH and Bailey AJ (2000) The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 43,550-557.
39. Villuendas G, San Millan JL, Sancho J and Escobar-Morreale HF (2002) The -597 G→A and -174 G→C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 87,1134-1141.
40. Wild RA (2002) Polycystic ovary syndrome: A risk for coronary artery disease? Am J Obstet Gynecol 180,35-43.
41. Wild RA, Painter PC, Coulson PB, Carruth KB and Ranney GB (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61,946-951.
42. Wild RA, Alaupovic P and Parker IJ (1992) Lipid and apolipoprotein abnormalities in hirsute women. The association with insulin resistance. Am J Obstet Gynecol 166,1191-1196, discussion 1196-1197.